Research Topics
Species | G K WilcockSummaryAffiliation: University of Bristol Country: UK Publications
| Collaborators
|
Detail Information
Publications
Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's diseaseZ K van Helmond
Dementia Research Group, Institute of Clinical Neurosciences, Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Bristol, UK
Neuropathol Appl Neurobiol 33:317-27. 2007..Our findings suggest that alterations in the expression of vascular CAV-1 and CAV-2 are unlikely to play a role in the development of CAA in AD...- Dementia with Lewy bodiesG K Wilcock
Department of Care of the Elderly, University of Bristol, Frenchay Hospital, BS16 1LE, Bristol, UK
Lancet 362:1689-90. 2003 - Memantine for the treatment of dementiaGordon K Wilcock
Department of Care of the Elderly, University of Bristol, UK
Lancet Neurol 2:503-5. 2003..The efficacy of memantine in vascular dementia also requires further investigation... 
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study GroupG K Wilcock
Department of Care of the Elderly, Frenchay Hospital, University of Bristol, Bristol BS16 1LE
BMJ 321:1445-9. 2000..To evaluate the efficacy and safety of galantamine in the treatment of Alzheimer's disease...- The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trialsG K Wilcock
Department of Care of the Elderly, University of Bristol, UK
Int J Geriatr Psychiatry 17:175-83. 2002..Data Extraction The reviewers selected trials for inclusion. Individual patient data were sought, but when these could not be retrieved summary data were extracted from published papers... - Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptorP H Holden
Department of Medicine Care of the Elderly, Bristol Royal Infirmary, UK
Nat Biotechnol 15:668-72. 1997..Recombinant protein binds to NGF and can inhibit NGF bioactivity both in vitro and in vivo... - How are quality of life ratings made? Toward a model of quality of life in people with dementiaL M T Byrne-Davis
Department of Care of the Elderly, Department of Clinical Science at North Bristol, University of Bristol, UK
Qual Life Res 15:855-65. 2006..The fact that so few of the participants talked about disease-orientated issues challenges the large cognitive components included in many QOL measures for use with people with dementia... - APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta proteinK Chalmers
Department of Care of the Elderly, Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK
Neuropathol Appl Neurobiol 29:231-8. 2003..These findings indicate that possession of the APOE epsilon 4 allele favours vascular over parenchymal accumulation of A beta in AD. This may influence the pathogenesis of neurodegeneration in epsilon 4-associated AD... - Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's diseaseS Williams
Care of the Elderly, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Bristol, UK
Neuropathol Appl Neurobiol 31:414-21. 2005..We propose that both CAA and peri-vascular accumulation of hyperphosphorylated tau may be a consequence of elevated levels of soluble A beta around cortical arteries and arterioles... - Neuronal death in brain infarcts in manS Love
Departments of Neuropathology, Care of the Elderly, Frenchay Hospital, Bristol, UK
Neuropathol Appl Neurobiol 26:55-66. 2000.... - Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's diseaseS Love
Department of Neuropathology, Frenchay Hospital, Bristol, UK
Brain 122:247-53. 1999..Our findings indicate that there is enhanced PARP activity in Alzheimer's disease and suggest that pharmacological interventions aimed at inhibiting PARP may have a role in slowing the progression of the disease... - Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotypeS J Allen
Department of Medicine Care of the Elderly University of Bristol, Bristol Royal Infirmary, UK
Neurosci Lett 239:33-6. 1997..This has important significance for the interpretation of the cholinergic deficits found in Alzheimer's disease... - Recombinant human nerve growth factor for clinical trials: protein expression, purification, stability and characterisation of binding to infusion pumpsS J Allen
Molecular Neurobiology Unit, University Research Centre for Neuroendocrinology Care of the Elderly, University of Bristol, BS2 8HW, Bristol, UK
J Biochem Biophys Methods 47:239-55. 2001..Tests were also carried out to monitor release of protein from infusion pumps and catheters for intracerebroventricular administration (icv). Initial problems with non-specific binding were overcome using a blocking formula... - Attentional control in Alzheimer's diseaseA D Baddeley
Departments of Experimental Psychology and Care of the Elderly, University of Bristol, UK
Brain 124:1492-508. 2001..These results suggest a need to fractionate executive processes, and reinforce earlier evidence for a specific dual-task processing deficit in Alzheimer's disease... - Failure to correlate C. pneumoniae with late onset Alzheimer's diseaseG S Taylor
Bristol Public Health Laboratory, University of Bristol, Frenchay Hospital, Bristol, UK
Neurology 59:142-3. 2002 - The pupillary light reflex in aging and Alzheimer's diseaseA Tales
Burden Neurological Institute, Frenchay Hospital, Bristol, England, United Kingdom
Aging (Milano) 13:473-8. 2001.... - Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's diseaseS J Allen
Molecular Neurobiology Unit, Department of Medicine Care of the Elderly, University of Bristol, Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom
Biochem Biophys Res Commun 264:648-51. 1999..This may have important consequences for the neurotrophic support of vulnerable neurons in AD... - Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccinationK Vedhara
Department of Medicine, University of Bristol, UK
Lancet 353:627-31. 1999..We investigated whether antibody responses to influenza vaccination differed between carers and a control group, and the relation of the antibody response to the hypothalamic-pituitary-adrenal (HPA) axis... - Common variants of ACE contribute to variable age-at-onset of Alzheimer's diseasePatrick G Kehoe
Department of Care of the Elderly, The John James Building, Frenchay Hospital, University of Bristol, UK
Hum Genet 114:478-83. 2004..These results provide an important complement to existing AD risk data, confirming that ACE harbors sequence variants that contribute to aspects of AD pathology... - APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's diseaseKaty A Chalmers
University of Bristol, Department of Care of the Elderly, Frenchay Hospital, Bristol BS16 1LE, UK
Neuroreport 15:95-8. 2004..Here we report that polymorphisms within the APOE promoter, ACE1 and CYP46 gene are not risk factors for AD and are not associated with parenchymal or vascular accumulation of Abeta... - Premorbid effects of APOE on synaptic proteins in human temporal neocortexSeth Love
Department of Neuropathology, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK
Neurobiol Aging 27:797-803. 2006..01). APOE influences the concentration of synaptic proteins in normal superior temporal cortex and may thereby affect the response to injury, and the risk and outcome of a range of neurologic diseases... - Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's diseaseDoris Culpan
Department of Care of the Elderly, University of Bristol, John James Buildings, Frenchay Hospital, Frenchay, Bristol, BS16 1LE, UK
Neurosci Lett 350:61-5. 2003..014, Fisher's exact test) suggesting that the 2-1-2 haplotype may be protective against AD... - alpha- and beta-secretase: profound changes in Alzheimer's diseaseSusan J Tyler
Molecular Neurobiology Unit, URCN Care of the Elderly University of Bristol, Bristol Royal Infirmary, Bristol, UK
Biochem Biophys Res Commun 299:373-6. 2002..Eighty percent of Alzheimer brains examined had an increase in beta-secretase, a decrease in alpha-secretase, or both; which may account for the means by which the majority of people develop Alzheimer's disease... - APOE and cerebral amyloid angiopathy in the elderlySeth Love
Department of Neuropathology, Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK
Neuroreport 14:1535-6. 2003..028). Possession of epsilon4 does not by itself confer an increased risk of CAA but may be associated with reduced longevity even in the absence of AD or cerebral haemorrhage... - Enhancement of antibody responses to influenza vaccination in the elderly following a cognitive-behavioural stress management interventionKav Vedhara
MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol, UK
Psychother Psychosom 72:245-52. 2003.... - Haplotypes extending across ACE are associated with Alzheimer's diseasePatrick G Kehoe
Department of Care of the Elderly, University of Bristol, The John James Building, Frenchay Hospital, Bristol, UK
Hum Mol Genet 12:859-67. 2003..Results support a model whereby decreased ACE activity may influence AD susceptibility by a mechanism involving beta-amyloid metabolism... - Patterns of clinically detectable treatment effects with galantamine: a qualitative analysisChristine Joffres
Geriatric Medicine Research Unit, Queen Elizabeth II Health Sciences Centre, Halifax, Canada
Dement Geriatr Cogn Disord 15:26-33. 2003..Clinicians appear to be skeptical of cognitive changes not supported by like changes in function or behaviour... 
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trialGordon K Wilcock
University of Oxford, John Radcliffe Hospital, Oxford, UK
Lancet Neurol 7:483-93. 2008..We aimed to test the effects of tarenflurbil, a selective Abeta(42)-lowering agent (SALA), on cognition and function in patients with mild to moderate AD...- Loss of perineuronal net N-acetylgalactosamine in Alzheimer's diseaseShabnam Baig
Department of Clinical Science at North Bristol, Care of the Elderly, Frenchay Hospital, University of Bristol, Bristol, UK
Acta Neuropathol 110:393-401. 2005..This could in turn lead to increased activity of the glutamatergic and other neurons onto which they synapse... - Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studiesGordon K Wilcock
From the Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Headington, UK
J Clin Psychiatry 69:341-8. 2008..The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline... - Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's diseaseDoris Culpan
Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Sciences at North Bristol, University of Bristol, John James Buildings, Frenchay Hospital, Frenchay, Bristol, BS16 1LE, United Kingdom
Neurosci Lett 408:141-5. 2006..Levels of IL-10 protein and gene expression examined also did not appear to be related to AD. Despite this being a relatively small sample, these data suggest that IL-10 does not play a major role in the development of AD... - Protein and gene expression of tumour necrosis factor receptors I and II and their promoter gene polymorphisms in Alzheimer's diseaseDoris Culpan
Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Sciences at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol, United Kingdom
Exp Gerontol 42:538-44. 2007..Our findings suggest that TNF-RI and -RII promoter gene polymorphisms and variations in protein and gene expression of these receptors are unlikely to play a major role in the development of AD... - Specific AD impairment in concurrent performance of two memory tasksSarah E MacPherson
Human Cognitive Neuroscience, Department of Psychology, University of Edinburgh, Edinburgh, UK
Cortex 43:858-65. 2007.... - Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?Patrick G Kehoe
Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol
Lancet Neurol 6:373-8. 2007.... - Galantamine in Alzheimer's diseaseGeorge Razay
University of Oxford, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, UK
Expert Rev Neurother 8:9-17. 2008..The magnitude of the treatment effect is similar to that of other cholinesterase inhibitors. Adverse events experienced by patients treated with galantamine are usually mild, gastrointestinal and may improve with dose reduction... - Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brainMia E L Blomqvist
Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
Neurobiol Aging 26:795-802. 2005..Results indicate that alleles of IDE contribute to variability in A beta deposition in the AD brain and suggest that this relationship may have relevance for the degree of cognitive dysfunction in AD patients... - Herpesviruses in brain and Alzheimer's diseaseWoan-Ru Lin
Department of Optometry and Neuroscience, UMIST, Manchester, UK
J Pathol 197:395-402. 2002.... - Absence of Chlamydia pneumoniae in brain of vascular dementia patientsMatthew A Wozniak
Department of Optometry and Neuroscience, Molecular Neurobiology Laboratory, University of Manchester Institute of Science and Technology, Manchester M60 1QD, UK
Neurobiol Aging 24:761-5. 2003..025 IFU. Our results do not support a role for Cpn in the aetiology of VaD, either in the 83% of patients in whose brains we detected CMV, or in the remaining 17% without CMV in brain... - Prediction rules for computed tomography in the dementia assessment: do they predict clinical utility of CT?Kelly A Condefer
Department of Care of the Elderly, Division of Medicine, University of Bristol, Bristol, UK
Int J Geriatr Psychiatry 18:285-7. 2003.... - The effects of galantamine treatment on caregiver time in Alzheimer's diseaseMary Sano
Mount Sinai School of Medicine Veterans Affairs Hospital, Bronx, NY 10468, USA
Int J Geriatr Psychiatry 18:942-50. 2003..The aim of the study was to determine whether the clinical benefits of galantamine for patients with Alzheimer's disease lead to benefits for caregivers... - Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolismHagit Katzov
Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
Hum Mutat 23:358-67. 2004..Results indicate that variants of ABCA1 may affect the risk of AD, providing further support for a genetic link between AD and cholesterol metabolism... - Clinical utility of computed tomography in the assessment of dementia: a memory clinic studyKelly A Condefer
Department of Neurology, The Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Int J Geriatr Psychiatry 19:414-21. 2004..To define the influence of computed tomography (CT) on clinical decision-making in the outpatient evaluation of dementia... - Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trialsAnne Whitehead
The University of Reading, Medical and Pharmaceutical Statistics Research Unit, Reading, UK
Int J Geriatr Psychiatry 19:624-33. 2004..The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD)... - Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patientsMatthew A Wozniak
Molecular Neurobiology Laboratory, Faculty of Life Sciences, The University of Manchester, Manchester, United Kingdom
J Med Virol 75:300-6. 2005..The HSV1 results confirm the original PCR findings that show the presence of HSV1 DNA sequences in many elderly brains, and indicate also that the whole functional HSV1 genome is present, and that the virus has replicated... - The future of Age and AgeingGordon K Wilcock
Age Ageing 31:1. 2002